Does ERBLAN Surgical, Inc. manufacture surgical devices?

No.  ERBLAN only envisions and patents innovative inventions for the surgical field of medicine.  ERBLAN does make proof-of-concept prototypes, but is not involved in full-scale manufacturing, regulatory approval, or sales.

What experience does ERBLAN have in the surgical arena?

ERBLAN's founder, Professor Blanco of MIT, has over two decades of experience designing and patenting medical devices.  His innovations have included accommodating lenses for ophthalmology, microstaplers, and assisting devices for laparoscopic procedures.

Are these devices patented internationally?

The ERBLAN intellectual property (IP) portfolio is patented broadly and deeply in virtually all international markets.  Extensive investment has been made in protecting these inventions from the Far East to South Africa, from Europe to Australia.  All devices and mechanisms are protected under method of use and design claims.  ERBLAN is also active in securing additional claims for their inventions.  The preeminent law firm Oblon, Spivak, McClelland, Maier and Neustadt continues to develop and secure the ERBLAN IP portfolio.

What type of business deal structure is ERBLAN offering?

Ideally, ERBLAN would like to license its IP for the worldwide market, to an organization that has the capacity to bring these innovative concepts to the broadest market and bring these breakthrough safety features rapidly into human use.  ERBLAN will also entertain licensing its IP into territorial "carve outs" outside of the US.

Has ERBLAN obtained regulatory approval, or formal safety claims, for its devices?

ERBLAN has been assured in preliminary discussions that obtaining regulatory approval for its trocars, insufflator needles, and gas seals will be straightforward and uncomplicated.  Obtainment of safety claims, however, has become an arduous task in recent years.  In the United States, the FDA will only accept convincing human data from well-constructed clinical trials before granting these types of assertions.  

We anticipate that the devices built upon ERBLAN concepts will be able to apply for human safety claims once an adequate amount of follow-up data becomes available after widespread use.  At this time, live animal testing has been tremendously encouraging with regard to the safety characteristics of the ERBLAN shielding mechanism.

How might an interested party obtain more information about the ERBLAN offering?

Interested parties may contact ERBLAN for additional information.  If the basic requirements for a relationship appear to be present, ERBLAN would request to have further discussions under an agreement of confidentiality.  We will be able to arrange face-to-face meetings and hands-on demonstrations of the devices.